Latest news with #Biotech
Yahoo
2 days ago
- Business
- Yahoo
Biotech stocks dip as Trump administration mulls patent fee overhaul
-- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system. According to The Wall Street Journal, Commerce Department officials are discussing a plan to charge patent holders between 1% and 5% of their overall patent value. This potential change, being considered by Commerce Secretary Howard Lutnick as part of efforts to raise revenue and reduce the government's budget deficit, could generate tens of billions of dollars. The proposed fee structure would represent a fundamental shift in the 235-year-old patent system, which currently requires patent holders to pay relatively modest flat fees totaling up to approximately $10,000 over multiple years. Under the new system, these costs would increase dramatically for many patent holders, functioning essentially as a property tax on intellectual property. This potential change could have significant implications for biotech companies, which rely heavily on patent protection for their drug developments and innovations. The pharmaceutical and biotechnology sectors typically maintain extensive patent portfolios to protect their research investments and ensure market exclusivity for their products. The news particularly affected major players in the biotech space, with companies like Pfizer (NYSE:PFE) trading lower during Monday's session as investors assessed the potential impact of higher patent-related costs on future profitability. Related articles Biotech stocks dip as Trump administration mulls patent fee overhaul Apollo economist warns: AI bubble now bigger than 1990s tech mania If Powell goes, does Fed trust go with him? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
3 days ago
- Business
- Globe and Mail
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Biotech giant Bristol-Myers Squibb Company ( BMY ) is scheduled to report second-quarter 2025 results on July 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $11.38 billion and $1.18 per share, respectively. Earnings estimate for 2025 has decreased to $6.37 from $6.76 per share over the past 30 days, while that for 2026 has declined to $6.03 from $6.04. BMY's Earnings Surprise History BMY has an excellent track record. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 20.16%. In the previously reported quarter, the company's earnings beat estimates by 19.21%. What Our Model Predicts for BMY Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Earnings ESP for BMY is -7.92%. The company currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Factors Influencing BMY's Q2 Results Total quarterly revenues are likely to have been impacted by a decline in sales from the legacy portfolio, which includes Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, among others. Generic competition for Sprycel, Revlimid, Abraxane and Pomalyst has likely pulled down revenues from this portfolio. The Zacks Consensus Estimate for Pomalyst's second-quarter sales is pegged at $727 million and our model estimate for the same is pinned at $690.8 million. Due to the impact of the Medicare Part D redesign, Eliquis' sales growth in the United States might have been tempered sequentially. The Zacks Consensus Estimate and our model estimate for Eliquis' second-quarter sales are pegged at $3.5 billion and $3.6 billion, respectively. Bristol-Myers collaborated with Pfizer ( PFE ) for Eliquis in 2007. Profits and losses are shared equally worldwide, except in certain countries where Pfizer commercializes Eliquis and pays BMY a sales-based fee. Nonetheless, this decline has likely been partially offset by an increase in growth product portfolio sales. Growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. Consistent label expansions in newer metastatic and adjuvant indications have likely maintained momentum for immuno-oncology drug Opdivo in the second quarter. The Zacks Consensus Estimate and our model estimate for Opdivo sales are pegged at $2.4 billion and $2.43 billion, respectively. The Zacks Consensus Estimate and our model estimate for Orencia sales are pegged at $909 million and $871 million, respectively. The Zacks Consensus Estimate and our model estimate for Yervoy sales are pegged at $652 million and $653.7 million, respectively. Reblozyl posted solid growth in both the United States and international markets in the last reported quarter. Sales in the United States are being driven by strong demand due to a broad label in the first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes who may require transfusions. International sales growth, driven by strong launches in Europe and Japan, has also likely boosted sales of this drug in the second quarter. The Zacks Consensus Estimate and our model estimate for Reblozyl sales are pegged at $546 million and $502 million, respectively. Strong growth in Opdualag (first-line melanoma) demand in the United States and encouraging uptake in newly launched markets are likely to have fueled sales. The Zacks Consensus Estimate and our model estimate for Opdualag sales are pegged at $278 million and $269.8 million, respectively. Breyanzi sales have likely benefited due to its best-in-class profile and strong demand growth across all its approved indications. Camzyos sales have likely seen strong growth, driven by increased demand in the United States on the back of new patient starts and higher demand in newly launched markets outside the country. The drug is expected to record steady growth in 2025 due to its compelling efficacy and safety profile in obstructive HCM. The newly launched schizophrenia drug Cobenfy, too, is off to a solid start, and sales have likely grown sequentially in the second quarter. Sotyktu sales have likely been under pressure due to higher rebates. In April 2024, BMY announced a strategic cost-reduction plan that should result in approximately $1.5 billion savings by the end of 2025. Concurrent with the fourth-quarter results, BMY announced an expansion to its existing strategic productivity initiative, which will include approximately $2 billion in additional annualized cost savings by the end of 2027 (with approximately $1 billion to be achieved in 2025). Consequently, operating expenses are likely to have decreased in the to-be-reported quarter. BMY's Price Performance and Valuation Shares of BMY have lost 14.4% year to date against the industry 's growth of 2%. The stock has also underperformed the sector and the S&P 500 in this timeframe. Image Source: Zacks Investment Research Going by the price/earnings ratio, BMY's shares currently trade at 7.84x forward earnings, lower than its mean of 8.51x and 15.34x for the large-cap pharma industry. Investment Thesis for BMY Legacy portfolio sales accounted for 50% of total sales in the first quarter and a continued decline in its sales might have adversely impacted top-line growth. While drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to somewhat stabilize its revenue base, these drugs will take some time to fully offset the decline in legacy drug sales. Nonetheless, approval of additional new drugs and label expansion of top drugs should further diversify its pipeline. The approval of Cobenfy for schizophrenia broadens BMY's portfolio and validates the acquisition of Karuna Therapeutics. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. BMY made strategic acquisitions to augment its product portfolio, and these seem to be paying off now. However, there is a long way to go. On the other hand, the company has taken on colossal debt to finance these acquisitions. BMY recently announced a strategic collaboration agreement with BioNTech ( BNTX ) for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. BMY and BNTX will jointly share development and manufacturing costs along with profits on an equal basis. Stay Invested in BMY Stock While BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable, the company still has a hill to climb as of now. Irrespective of how the second-quarter results play out, we recommend prospective investors to wait and watch how BMY wades through these challenges before turning positive. For investors already owning the stock, staying invested would be a prudent move. The company's attractive dividend yield is a strong positive. You can see the complete list of today's Zacks #1 Rank stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Yahoo
3 days ago
- Business
- Yahoo
Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team
Janet Loesberg, PhRMA/Biotech veteran, brings medical and launch expertise. SUMMIT, N.J., July 28, 2025 /PRNewswire/ -- Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President. Dr. Loesberg brings a wealth of pharmaceutical and leadership expertise to Vascarta. She has served in executive global medical affairs and R&D roles at Blueprint Medicines, Janssen Pharmaceuticals (div. of Johnson & Johnson), Bristol-Myers Squibb, and Pfizer. She was a board member at Ambrx, a clinical stage biotech company. Most recently, as Senior Vice President of Blueprint Medicines, she was responsible for the medical strategy behind the successful launch of Ayvakit™ (avapritinib) for indolent systemic mastocytosis, a rare hematologic disorder. Her experience with the hematologic community will greatly benefit Vascarta as it develops Vasceptor® (VAS-101) for sickle cell disease. "We are thrilled to welcome Janet to Vascarta and look forward to leveraging her deep industry expertise and business transformation experience as we focus on developing Vasceptor® for sickle cell disease and osteoarthritis," said Richard Prince, PhD, Chief Executive Officer. "Janet is a world-class executive with a proven track record in developing and commercializing medicines and we expect her to contribute greatly to moving our company into the future." "I'm excited to join Vascarta with its promise to bring relief to patients suffering from chronic inflammatory diseases," Dr. Loesberg said. "My focus will be to accelerate the development of Vasceptor® and prepare for its launch. I'm excited to be working with the talented team at Vascarta and making their vision a reality." About Vascarta, Inc. Vascarta Inc. is a clinical stage pharmaceutical company developing efficient transdermal and transmucosal delivery of pharmaceuticals to address inflammatory conditions with an initial focus on sickle cell disease and osteoarthritis. To learn more, contact Vascarta Chairman, CEO & President, Dr. Richard Prince, at rprince@ Media requests should be directed to David Hymson at dhymson@ View original content to download multimedia: SOURCE Vascarta Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth
The global cell and gene therapy supply chain software market is set to expand from USD 0.27 billion in 2025 to USD 1.32 billion by 2035, at a CAGR of 15.2%. Driven by demand for advanced therapies, the market is enhanced by cloud-based technologies and key players like Azenta Life Sciences and Lonza. Cell and Gene Therapy Supply Chain Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to offering. The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies. The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems. Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users. The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023. Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years. Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future. The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions. Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered. Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength. Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook. Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings. Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements. Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain. Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs. Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth. Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include: Azenta Life Sciences Biocair BioLife Solutions CareDx Cryoport Lonza NMDP BioTherapies TraceLink TrakCel Veeva Systems Emerson LabVantage Solutions Marken MasterControl QuickSTAT Siemens Stafa Cellular Therapy Steiner STEMSOFT Software TECHNIDATA Thermo Fisher Scientific KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell and Gene Therapy Supply Chain CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
New Indian Express
5 days ago
- Health
- New Indian Express
Rotary to organise CPR camps, health checkups for frontline cops
BENGALURU: The June 4 stampede at Chinnaswamy Stadium that claimed 11 lives and left several police personnel injured, has shaken up Karnataka. There is a call by senior officers and civic leaders to train police and citizens in the skill of cardiopulmonary resuscitation (CPR). Throwing light on the toll law enforcement officers paid during the stampede, ADGP KV Sharath Chandra said, 'Our men and women in uniform need to be trained not just in riot control but in reviving a life. CPR is useful for both police and people.' Now, with heart attacks increasing among people in their 20s and 30s, CPR literacy has become essential. Rotary Bangalore Northwest has pledged to organize CPR training and health checkups for frontline police, especially armed and civil forces deployed on high-stress bandobast duty. Former police commissioner Bhaskar Rao, advising the public to step up during medical emergencies, said, 'Every second counts. You don't need a uniform to save a life, just training and courage.' Lakshmi Achuta, president of Rotary Bangalore Northwest and Principal Strategic Adviser, Biotech, at Biocon, said it is not enough to train only the police. 'Imagine how many lives could have been saved at the KSCA stampede if more people in the crowd knew CPR. It is about empowering everyone with a life-saving skill.' The movement has also gone global. Rajiv Thalla, based in the United States, has turned a personal heartbreak into a mission. After losing his 23-year-old son Rohan Rajiv to a sudden heart attack, he has taken it on himself to hold free CPR demonstrations, to ensure others don't suffer the same fate. He travels across cities, from Los Angeles to Lucknow, distributing educational material, and partnering with Rotary. His younger son, a doctor, stands by him. 'This isn't just about first aid, but first response. A few minutes can mean the difference between life and death. CPR gives you those minutes.'
